NCT01596816

Hypofractionated Stereotactic Boost in Prostate Cancer

Intermediate-risk Prostate Cancer : Assessment of Hypofractionated Stereotactic Boost - Prospective Phase II Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 76 (actual)
• Sponsor: Centre Oscar Lambret · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

hypofractionated stereotactic boost radiation (prostate) after normofractionated radiotherapy (prostate + seminal vesicles).

Detailed description

The aim of this study is to assess the safety of hypofractionated stereotactic boost radiation (prostate) after normofractionated radiotherapy (prostate + seminal vesicles).

Conditions

• Cancer

Interventions

Type	Name	Description
RADIATION	First part of treatment : Conformal irradiation	23 fractions (2 Gy/session), are delivered over 42 days maximum, for a total dose of 46 Gy
PROCEDURE	Fiducials placement	Placement of intra-prostatic markers for the tracking
RADIATION	Second part : hypofractionated stereotactic boost	3 fractions (6Gy/session) are delivered over 5 to 9 days (at least 48 hours between sessions) for a total dose of 18 Gy

Timeline

• Start date: 2010-08-31
• Primary completion: 2016-09-01
• Completion: 2018-09-01
• First posted: 2012-05-11
• Last updated: 2026-03-13

Locations

7 sites across 1 country: France